Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions

Inclusion Criteria: * the age of the patient is between 18 and 85; * no previous biopsy; * presence of multiple MRI visible lesions; * every MRI visible lesion is in accordance with the EAU guidelines for performing perilesional biopsy (PB) (PI-RADS ≥4 or PI-RADS =3, clinical suspicion of PCa); * a verified prostate-specific antigen (PSA) less than 50 ng/ml; * complete MRI data, and high MRI quality (Prostate Imaging Quality \[PI-QUAL\] V1.0 score ≥3); * the time interval between prostate biopsy and prostate MRI examination should not exceed one month; * patients with complete prostate biopsy pathological results; * patients with complete clinical information. Exclusion Criteria: * contraindication for MRI examination (i.e., in acute attack period such as high fever, coma, epilepsy, prone to cardiac arrest, claustrophobia, presence of ferrous metallic implants, or claustrophobia); * contraindication for prostate biopsy ((a) in the period of acute infection or fever; (b) hypertensive crisis; (c) in the decompensated stage of heart failure; (d) diseases with severe bleeding tendency; (e) poorly controlled complications of hypertension or diabetes; (f) patients with severe internal or external hemorrhoids, perianal or rectal lesions should not undergo transrectal biopsy); * a history of radiotherapy, chemotherapy, androgen deprivation therapy, or surgery for PCa; * patients with previous biopsy; * the absence of MRI-visible prostate lesions or presence of single suspicious lesions; * PI-RADS V2.1 \<3; * unqualified or incomplete MRI data; * the patient could not cooperate to complete the prostate biopsy; * the patients or their family members refused to participate in this study; * patients with incomplete clinical information.